|
EMEA-coordinated PROTECT project has been accepted for funding
|
01 May 2009 |
|
EMEA, EC and Health Canada agree implementation plan for confidentiality arrangement
|
14 April 2009 |
|
EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab)
|
20 February 2009 |
|
European Medicines Agency welcomes continuation of D:A:D study
|
04 February 2009 |
|
EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)
|
21 November 2008 |
|
EMEA recommends suspension of the marketing authorisation of Acomplia
|
24 October 2008 |
|
European Medicines Agency recommends update of product information of Tysabri
|
26 September 2008 |
|
European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines
|
28 July 2008 |
|
EMEA recommendation on use of angiotensin II receptor antagonists during pregnancy
|
25 April 2008 |
|
Wyeth Europa Ltd withdraws its marketing authorisation application for Pristiqs (desvenlafaxine)
|
13 March 2008 |
|
Actelion withdraws its application for an extension of indication for Zavesca
|
27 February 2008 |
|
Risk of peripheral neuropathy with Sebivo (telbivudine)
|
15 February 2008 |
|
EMEA recommends new warnings and contraindications for rosiglitazone
|
25 January 2008 |
|
EMEA recommends withdrawal of marketing authorisations for cough medicines containing clobutinol
|
19 October 2007 |